Cargando…

An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease

Sofosbuvir seems to be a revolutionary treatment for Hepatitis C-infected patients with advanced chronic kidney disease (CKD) but existing evidence is not quite adequate. The aim of this study was to evaluate the efficacy and safety of Sofosbuvir-based therapy without Ribavirin for all hepatitis C v...

Descripción completa

Detalles Bibliográficos
Autores principales: Majd Jabbari, Sara, Maajani, Khadije, Merat, Shahin, Poustchi, Hossein, Sepanlou, Sadaf G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875415/
https://www.ncbi.nlm.nih.gov/pubmed/33566846
http://dx.doi.org/10.1371/journal.pone.0246594
_version_ 1783649769479995392
author Majd Jabbari, Sara
Maajani, Khadije
Merat, Shahin
Poustchi, Hossein
Sepanlou, Sadaf G.
author_facet Majd Jabbari, Sara
Maajani, Khadije
Merat, Shahin
Poustchi, Hossein
Sepanlou, Sadaf G.
author_sort Majd Jabbari, Sara
collection PubMed
description Sofosbuvir seems to be a revolutionary treatment for Hepatitis C-infected patients with advanced chronic kidney disease (CKD) but existing evidence is not quite adequate. The aim of this study was to evaluate the efficacy and safety of Sofosbuvir-based therapy without Ribavirin for all hepatitis C virus genotypes among patients with advanced CKD. We conducted an updated systematic literature search from the beginning of 2013 up to June 2020. Sustained virologic response (SVR) rate at 12 and/or 24 weeks after the end of treatment, and adverse events in HCV-infected patients with advanced CKD were pooled using random effects models. We included 27 published articles in our meta-analyses, totaling 1,464 HCV-infected patients with advanced CKD. We found a substantial heterogeneity based on the I(2) index (P = 0.00, I(2) = 56.1%). The pooled SVR rates at 12 and 24 weeks after the end of Sofosbuvir-based treatment were 97% (95% Confidence Interval: 95–99) and 95% (89–99) respectively. The pooled SVR12 rates were 98% (96–100) and 94% (90–97) in patients under 60 and over 60 years old respectively. The pooled incidence of severe adverse events was 0.11 (0.04–0.19). The pooled SVR12 rate after completion of the half dose regimen was as high as the full dose treatment but it was associated with less adverse events (0.06 versus 0.14). The pooled SVR12 rate was 98% (91–100) in cirrhotic patients and 100% (98–100) in non-cirrhotic patients. The endorsement of Sofosbuvir-based regimen can improve the treatment of hepatitis C virus infection in patients with advanced CKD.
format Online
Article
Text
id pubmed-7875415
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-78754152021-02-19 An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease Majd Jabbari, Sara Maajani, Khadije Merat, Shahin Poustchi, Hossein Sepanlou, Sadaf G. PLoS One Research Article Sofosbuvir seems to be a revolutionary treatment for Hepatitis C-infected patients with advanced chronic kidney disease (CKD) but existing evidence is not quite adequate. The aim of this study was to evaluate the efficacy and safety of Sofosbuvir-based therapy without Ribavirin for all hepatitis C virus genotypes among patients with advanced CKD. We conducted an updated systematic literature search from the beginning of 2013 up to June 2020. Sustained virologic response (SVR) rate at 12 and/or 24 weeks after the end of treatment, and adverse events in HCV-infected patients with advanced CKD were pooled using random effects models. We included 27 published articles in our meta-analyses, totaling 1,464 HCV-infected patients with advanced CKD. We found a substantial heterogeneity based on the I(2) index (P = 0.00, I(2) = 56.1%). The pooled SVR rates at 12 and 24 weeks after the end of Sofosbuvir-based treatment were 97% (95% Confidence Interval: 95–99) and 95% (89–99) respectively. The pooled SVR12 rates were 98% (96–100) and 94% (90–97) in patients under 60 and over 60 years old respectively. The pooled incidence of severe adverse events was 0.11 (0.04–0.19). The pooled SVR12 rate after completion of the half dose regimen was as high as the full dose treatment but it was associated with less adverse events (0.06 versus 0.14). The pooled SVR12 rate was 98% (91–100) in cirrhotic patients and 100% (98–100) in non-cirrhotic patients. The endorsement of Sofosbuvir-based regimen can improve the treatment of hepatitis C virus infection in patients with advanced CKD. Public Library of Science 2021-02-10 /pmc/articles/PMC7875415/ /pubmed/33566846 http://dx.doi.org/10.1371/journal.pone.0246594 Text en © 2021 Majd Jabbari et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Majd Jabbari, Sara
Maajani, Khadije
Merat, Shahin
Poustchi, Hossein
Sepanlou, Sadaf G.
An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease
title An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease
title_full An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease
title_fullStr An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease
title_full_unstemmed An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease
title_short An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease
title_sort updated systematic review and meta-analysis on efficacy of sofosbuvir in treating hepatitis c-infected patients with advanced chronic kidney disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875415/
https://www.ncbi.nlm.nih.gov/pubmed/33566846
http://dx.doi.org/10.1371/journal.pone.0246594
work_keys_str_mv AT majdjabbarisara anupdatedsystematicreviewandmetaanalysisonefficacyofsofosbuvirintreatinghepatitiscinfectedpatientswithadvancedchronickidneydisease
AT maajanikhadije anupdatedsystematicreviewandmetaanalysisonefficacyofsofosbuvirintreatinghepatitiscinfectedpatientswithadvancedchronickidneydisease
AT meratshahin anupdatedsystematicreviewandmetaanalysisonefficacyofsofosbuvirintreatinghepatitiscinfectedpatientswithadvancedchronickidneydisease
AT poustchihossein anupdatedsystematicreviewandmetaanalysisonefficacyofsofosbuvirintreatinghepatitiscinfectedpatientswithadvancedchronickidneydisease
AT sepanlousadafg anupdatedsystematicreviewandmetaanalysisonefficacyofsofosbuvirintreatinghepatitiscinfectedpatientswithadvancedchronickidneydisease
AT majdjabbarisara updatedsystematicreviewandmetaanalysisonefficacyofsofosbuvirintreatinghepatitiscinfectedpatientswithadvancedchronickidneydisease
AT maajanikhadije updatedsystematicreviewandmetaanalysisonefficacyofsofosbuvirintreatinghepatitiscinfectedpatientswithadvancedchronickidneydisease
AT meratshahin updatedsystematicreviewandmetaanalysisonefficacyofsofosbuvirintreatinghepatitiscinfectedpatientswithadvancedchronickidneydisease
AT poustchihossein updatedsystematicreviewandmetaanalysisonefficacyofsofosbuvirintreatinghepatitiscinfectedpatientswithadvancedchronickidneydisease
AT sepanlousadafg updatedsystematicreviewandmetaanalysisonefficacyofsofosbuvirintreatinghepatitiscinfectedpatientswithadvancedchronickidneydisease